Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Mian, Afsar A ^a   Metodieva, Anna ^a   Badura, Susanne ^a   Khateb, Mamduh ^b   Ruimi, Nili ^b   Najajreh, Yousef ^c   Ottmann, Oliver G ^a   Mahajna, Jamal ^b,d   Ruthardt, Martin ^a,e  

^a GOETHE UNIVERSITY   (Germany)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^c AL QUDS UNIVERSITY   (Palestine)

^d TEL HAI COLLEGE   (Israel)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

" gatekeeper" mutation T315I; Abl kinase inhibitors; Allosteric inhibition; BCR ABL; Molecular therapy; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GNF 2; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOSTERISM; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL GROWTH; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; FIBROBLAST; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84866148220     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-411     Document Type: Article

References (17)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247(4944):824-830. 10.1126/science.2406902, 2406902.
2. Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A 2009, 106(39):16616-16621. 10.1073/pnas.0908107106, 2757818, 19805346.
3. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, Ruthardt M. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 2008, 122(12):2744-2752. 10.1002/ijc.23467, 18366061.
4. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 2009, 23(12):2242-2247. 10.1038/leu.2009.194, 19798092.
5. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003, 22(47):7389-7395. 10.1038/sj.onc.1206942, 14576846.
6. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6(10):834-848. 10.1038/nrd2324, 17853901.
7. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004, 5(1):33-44. 10.1038/nrm1280, 14708008.
8. Badura S, Tesanovic T, Pfeifer H, Liebermann M, Falkenburg JHF, Ruthardt M, Ottmann OG. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in long-term cultures of acute lymphoblastic leukemia reveal a distinct role of mTORC2 submitted for publication.
9. Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D, Marijt EW, Ottmann OG, Willemze R, Falkenburg JH. Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 2009, 37(3):376-385. 10.1016/j.exphem.2008.11.002, 19135770.
10. Prichard MN, Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990, 14(4-5):181-205.
11. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006, 2(2):95-102. 10.1038/nchembio760, 16415863.
12. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463(7280):501-506. 10.1038/nature08675, 2901986, 20072125.
13. Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, Ottmann OG, Ruthardt M. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 2009, 23(9):1614-1621. 10.1038/leu.2009.69, 19369965.
14. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008, 15(10):1109-1118. 10.1038/nsmb.1486, 2575426, 18794843.
15. Iacob RE, Zhang J, Gray NS, Engen JR. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 2011, 6(1):e15929. 10.1371/journal.pone.0015929, 3018526, 21264348.
16. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008, 49(4):615-619. 10.1080/10428190801896103, 18398720.
17. Patwardhan P, Resh MD. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol Cell Biol 2010, 30(17):4094-4107. 10.1128/MCB.00246-10, 2937550, 20584982.